XYRA Announces the Issuance of a Fifth New US Patent in a Series of Patents Which Protect the Use of Budiodarone in the Management of Atrial Fibrillation till after 2040

XYRA United Kingdom England California

Budiodarone shown in Phase 2 to reduce atrial fibrillation symptoms and long episodes of atrial fibrillation (LEAF)FDA gives guidance on steps necessary to gain approval and incorporate wearable AF monitoring devices into label for budiodaroneFive granted US patents align with FDA's guidance and protect the drug and label till after 2040View original content:https://www.prnewswire.co.uk/news-releases/xyra-announces-the-issuance-of-a-fifth-new-us-patent-in-a-series-of-patents-which-protect-the-use-of-budiodarone-in-the-management-of-atrial-fibrillation-till-after-2040-302436586.html